Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M206,467Revenue $M49,605Net Margin (%)18.7Altman Z-Score2.8
Enterprise Value $M214,995EPS $1.4Operating Margin %25.9Piotroski F-Score6
P/E(ttm)23.1Beneish M-Score-2.7Pre-tax Margin (%)25.4Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %3.0Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %5.0Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow16.4y-y EBITDA Growth Rate %-14.2ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %3.2PEG4.6ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,158ROIC % (ttm)12.1Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKahn Brothers 2015-03-31 Reduce-0.39%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 3.83%1,811,016
PFEJames Barrow 2015-03-31 Reduce-0.32%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 12.24%55,080,222
PFENWQ Managers 2015-03-31 Reduce-0.16%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 6.64%5,927,532
PFEJoel Greenblatt 2015-03-31 Add0.15%$31.16 - $35.05
($33.51)
$ 33.37-0%Add 38.84%1,972,788
PFECharles Brandes 2015-03-31 Reduce-0.07%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 2.37%6,123,536
PFEDavid Dreman 2015-03-31 Add0.03%$31.16 - $35.05
($33.51)
$ 33.37-0%Add 70.38%25,202
PFEMario Gabelli 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 5.80%896,431
PFEDodge & Cox 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.89%46,776,959
PFERichard Pzena 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.50%2,159,618
PFEFirst Eagle Investment 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.12%5,266,820
PFEJohn Keeley 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 1.27%98,689
PFEKen Fisher 2015-03-31 Add$31.16 - $35.05
($33.51)
$ 33.37-0%Add 0.04%31,208,271
PFEKahn Brothers 2014-12-31 Reduce-0.49%$27.7 - $32.09
($30.23)
$ 33.3710%Reduce 5.14%1,883,217
PFEFirst Eagle Investment 2014-12-31 Add0.39%$27.7 - $32.09
($30.23)
$ 33.3710%Add 3786.85%5,272,943
PFERichard Pzena 2014-12-31 Buy 0.36%$27.7 - $32.09
($30.23)
$ 33.3710%New holding2,170,568
PFEVanguard Health Care Fund 2014-12-31 Add0.32%$27.7 - $32.09
($30.23)
$ 33.3710%Add 29.88%19,395,622
PFEMichael Price 2014-12-31 Sold Out -0.17%$27.7 - $32.09
($30.26)
$ 33.3710%Sold Out0
PFEKahn Brothers 2014-09-30 Reduce-0.59%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 6.56%1,985,161
PFEMichael Price 2014-09-30 Reduce-0.22%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 56.02%47,100
PFEFirst Eagle Investment 2014-09-30 Reduce-0.16%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 94.11%135,661
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2015-06-11Sell26,000$34.39-2.97view
HILL CHARLES HExecutive Vice President 2015-05-29Sell42,870$34.92-4.44view
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$34-1.85view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.62-3.61view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.46-3.16view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-3.92view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-4.25view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.23-2.51view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.3-2.71view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-10Sell9,000$33.78-1.21view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    Despite Recent Downgrade, This Ecommerce Giant is a Buy Jun 29 2015 
    Paul Tudor Jones' Top Three Stocks Deliver Positive Returns Jun 24 2015 
    Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
    A Look at James Barrow's Investment in Pfizer Jun 16 2015 
    Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
    Ken Fisher Adds to His Pfizer Position May 27 2015 
    Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
    Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 

    More From Other Websites
    6:13 am Pfizer and GlaxoSmithKline (GSK) JV ViiV Healthcare enters... Jul 05 2015
    Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount Jul 03 2015
    Hospira wins French biosimilar drug tender at 45 pct discount Jul 03 2015
    PRESS DIGEST- British Business - July 3 Jul 02 2015
    Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of... Jul 02 2015
    Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of... Jul 02 2015
    5 U.S. Large-Caps Facing Declining Revenue Jul 02 2015
    Icagen, acquired by Pfizer in 2011, turns next chapter Jul 02 2015
    Icagen Re-launched Through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel... Jul 02 2015
    Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel... Jul 02 2015
    ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of... Jul 02 2015
    [video]U.S. Companies Look to the U.K. for Investment Opportunites Jul 01 2015
    U.S. doctors, hospitals reap $6.5 bln from drug and device makers -report Jun 30 2015
    Big pharma to be grilled on tax avoidance Jun 30 2015
    Why Jazz Pharmaceuticals Is Winning Jun 29 2015
    Bank controls add to headaches for Greece's pharmacists Jun 29 2015
    Bank controls add to headaches for Greece's pharmacists Jun 29 2015
    Dow falls 225 points, in the red for the year amid Greece; VIX spikes 24% Jun 29 2015
    Is Big Pharma Advertising Getting Out of Control? Jun 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    SEENSCO
    ReplySEENSCO - 1 year ago
    PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK